(d) whether it is a fact that none of these communications has been replied t<>;

(e) what are the details of drug issues on which communications have been sent and what are the reasons for not. giving leplies to such communications;

(f) whether it U also a fact that certain complaints about corrupt practices by cer tain officials have also been received; and

(g) if so, what is the nature of comp Iaints, details of officers concerned and action taken against each?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL); (a) to (g) The information is being compiled and will b_e laid on the Table of the House.

Committees on drug industry

1393. SHRI RATAN KUMARI; Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that bis Minis try ha_s appointed a number of committees on drug issues;

(b) if so how many committees wer< appointed after the announcement o Measures, 1986;

(c) what were the terms of refereno of each committee and what are the nami of the members of each committee ar when each committee was appointed;

(d) whether it is a fact that most c these committees have submitted their t ports by the 15th July, 1989; (e) if so, what are the names of ti committees which have submitted the report by the 15th My, 1989;

(f) what are the details of repoi which have been accepted by his Minist and by when the remaining reports a likely to be accepted; and

(g) what are the details of the co minees which havt yet to submit th reports and by when they are Mkely to ubmit the same?

THE MINTSTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF HEMICALs AND PETRO-CHEMI-:ALS IN THE MINISTRY OF INDUSRY (SHRI P. NAMGYAL): (a) Yes, ir.

(b) to (g). The required details of b« extent available will be collected and aid on the Table of the House.

Prices of Dexona range formulations

1394. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of IN-DUSTRY be pleased to refer to the answer to Unstarred Question 1611 given in the Rajya Sabha on the 8th May, 1989 and state:

(a) what ar_e tbe prices fixed for Daxo-na range of formulations under DPCO, 1987 and when such prices were fixed;

(b) what were the prices of these for-mulations before such fixation;

(c) when these prices were implemented and what are the prices at which these formulations are being sold;

(d) what was the price of each pack and strength of these formulations under DPCO, 1979 and when these prices were fixed;

(e) what wa« the bulk drug price on which prices under DPCO, 1979 were fixed and what is the bulk drug price taken now;

(f) whether it is a fact that prices of these formulations have been overcharged;

(g) whether hi_s Ministry has assessed the overcharging; and

(h) if so, what is the assessment and if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY I AFFAIRS AND THE MINISTER OF STATE TN THE DEPARTMENT OF